2023 ASCO

GI Cancer ASCO 2023 Highlights with Dr. Muhammad Shaalan Beg

Discussing GI (Gastrointestinal) Cancer ASCO 2023 Highlights, focusing on practice-changing studies with Dr. Muhammad Shaalan Beg, Co-Leader Gastrointestinal Oncology, Adjunct Associate Professor of Internal Medicine, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center. Covering three important studies:

– PROSPECT: ph III trial of neoad chemoRT vs neoadj FOLFOX chemo with selective use of chemoRT, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC)

– NORPACT-1: Short-course neoadj FOLFIRINOX vs upfront surgery for resectable pancreatic head cancer

– NAPOLI 3: ph III trial in mets pancreatic ductal adenocarcinoma pts, liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) vs nab-paclitaxel + gemcitabine

– IMbrave050: Efficacy, safety and patient-reported outcomes (PROs) from the phase III IMbrave050 trial of adj atezo + bev vs active surveillance in pts with HCC


2023 ASCO

Lung Cancer ASCO 2023 Highlights with Dr. Charu Aggarwal

Discussing Lung Cancer ASCO 2023 Highlights, focusing on practice changing studies with Dr. Charu Aggarwal, Director, Precision Oncology Innovation, Associate Professor of Lung Cancer Excellence at Penn Medicine. Covering three important studies:

– ADAURA trial update with increase OS with adjuvant Osimertinib

– KEYNOTE 789 – Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant

– KEYNOTE 671 – Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC

2023 ASCO

Breast Cancer ASCO 2023 Highlights with Dr. Stephanie Graff

Discussing Breast Cancer ASCO 2023 Highlights, focusing on practice-changing studies with Dr. Stephanie Graff, Director of Breast Oncology, Associate Professor of Medicine, Lifespan Cancer Institute, Brown University. Covering three important studies:

– NATALEE Phase III study of ribociclib (RIBO) + endocrine therapy (ET) in HR+ patients

– SONIA challenging the need for first-line use of a CDK4/6 Inhibitor in HR+ advanced breast cancer patients

– X-7/7 trial evaluating fixed-dose capecitabine compared to standard dose capecitabine in metastatic breast cancer

2023 ASCO

GU ASCO 2023 Highlights with Dr. Petros Grivas

Discussing GU ASCO 2023 Highlights – practice changing / informing studies with Dr. Petros Grivas, Clinical Director of Genitourinary Cancer Program, Professor, Division of Medical Oncology at Fred Hutch Cancer Center.

Subscribe Now


Dr. Rahul

Dr. Rahul is a Chief of Medical Oncology, making up one-half of the ‘Oncology Brothers.’ He is a valued member of the Guthrie Corning Cancer Center, contributing his extensive knowledge of technology